ACLARIS THERAPEUTICS INC's ticker is ACRS and the CUSIP is 00461U105. A total of 134 filers reported holding ACLARIS THERAPEUTICS INC in Q2 2021. The put-call ratio across all filers is 0.55 and the average weighting 0.8%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2024 | $8,658 | -85.2% | 6,982 | -87.4% | 0.00% | – |
Q4 2023 | $58,337 | -85.6% | 55,559 | -5.9% | 0.00% | -100.0% |
Q3 2023 | $404,472 | -41.9% | 59,047 | -12.0% | 0.00% | 0.0% |
Q2 2023 | $695,837 | +32.3% | 67,101 | +3.2% | 0.00% | 0.0% |
Q1 2023 | $526,052 | -49.6% | 65,025 | -2.0% | 0.00% | -50.0% |
Q4 2022 | $1,044,603 | +1.1% | 66,324 | +1.1% | 0.00% | 0.0% |
Q3 2022 | $1,033,000 | +19.4% | 65,616 | +5.8% | 0.00% | +100.0% |
Q2 2022 | $865,000 | -17.7% | 61,998 | +1.7% | 0.00% | 0.0% |
Q1 2022 | $1,051,000 | +8.8% | 60,986 | -8.2% | 0.00% | 0.0% |
Q4 2021 | $966,000 | -15.9% | 66,460 | +4.1% | 0.00% | 0.0% |
Q3 2021 | $1,149,000 | +9.2% | 63,821 | +6.6% | 0.00% | 0.0% |
Q2 2021 | $1,052,000 | +2046.9% | 59,896 | +26.5% | 0.00% | – |
Q1 2020 | $49,000 | -44.3% | 47,336 | +1.2% | 0.00% | – |
Q4 2019 | $88,000 | +72.5% | 46,787 | -1.4% | 0.00% | – |
Q3 2019 | $51,000 | -51.0% | 47,440 | 0.0% | 0.00% | – |
Q2 2019 | $104,000 | -68.7% | 47,440 | -14.4% | 0.00% | -100.0% |
Q1 2019 | $332,000 | -19.0% | 55,413 | 0.0% | 0.00% | 0.0% |
Q4 2018 | $410,000 | -31.0% | 55,413 | +35.5% | 0.00% | 0.0% |
Q3 2018 | $594,000 | -27.3% | 40,904 | -0.0% | 0.00% | -50.0% |
Q2 2018 | $817,000 | +32.2% | 40,907 | +16.0% | 0.00% | +100.0% |
Q1 2018 | $618,000 | -31.6% | 35,264 | -3.8% | 0.00% | -50.0% |
Q4 2017 | $904,000 | -2.9% | 36,645 | +1.6% | 0.00% | 0.0% |
Q3 2017 | $931,000 | -3.8% | 36,058 | +1.0% | 0.00% | 0.0% |
Q2 2017 | $968,000 | +46.2% | 35,696 | +60.8% | 0.00% | +100.0% |
Q1 2017 | $662,000 | +4.7% | 22,196 | -4.7% | 0.00% | 0.0% |
Q4 2016 | $632,000 | +22.7% | 23,296 | +15.9% | 0.00% | 0.0% |
Q3 2016 | $515,000 | +47.6% | 20,096 | +6.4% | 0.00% | 0.0% |
Q2 2016 | $349,000 | +51.1% | 18,896 | +54.7% | 0.00% | – |
Q1 2016 | $231,000 | -19.5% | 12,213 | +14.7% | 0.00% | -100.0% |
Q4 2015 | $287,000 | – | 10,650 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Foresite Capital Management IV, LLC | 2,808,034 | $29,119,313 | 14.32% |
Foresite Capital Management V, LLC | 1,258,243 | $13,047,980 | 9.53% |
GREAT POINT PARTNERS LLC | 1,941,581 | $20,134,195 | 3.94% |
Bain Capital Life Sciences Investors, LLC | 3,400,000 | $35,258,000 | 3.63% |
Aisling Capital Management LP | 434,455 | $4,505,298 | 2.21% |
SILVERARC CAPITAL MANAGEMENT, LLC | 651,400 | $6,755,018 | 2.09% |
VR Adviser, LLC | 1,040,754 | $10,792,619 | 1.73% |
Ikarian Capital, LLC | 796,300 | $8,257,631 | 1.32% |
Samsara BioCapital, LLC | 696,171 | $7,219,293 | 1.27% |
BRAIDWELL LP | 2,901,194 | $30,085,382 | 0.98% |